Cancer Pharmacology Laboratory
Frank M. Balis, MD, in the Cancer Pharmacology Laboratory focuses on optimizing the safety and efficacy of new and conventional anticancer drugs, on developing new drugs for childhood cancers and on devising new clinical trial designs and endpoints to expedite the development of new treatments.
Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. Cancer Chemother Pharmacol. 2015 Dec;76(6):1273-83. Epub 2015 Oct 20.
Fox E, Widemann BC, Pastakia D, Chen CC, Yang SX, Cole D, Balis FM.
Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy. Int J Pediatr Endocrinol. 2015;2015(1):3. Epub 2015 Feb 16. Lodish M, Gkourogianni A, Bornstein E, Sinaii N, Fox E, Chuk M, Marcus L, Akshintala S, Balis F, Widemann B, Stratakis CA.
Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma. Cancer Chemother Pharmacol. 2014 Nov;74(5):1047-55. Epub 2014 Sep 12.
Desai AV, Fox E, Smith LM, Lim AP, Maris JM, Balis FM.